ImmuPharma (LON:IMM) Stock Crosses Below 200 Day Moving Average – Should You Sell?

ImmuPharma plc (LON:IMMGet Free Report)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 8.24 and traded as low as GBX 6.50. ImmuPharma shares last traded at GBX 6.50, with a volume of 837,072 shares.

ImmuPharma Trading Down 2.1%

The stock has a fifty day simple moving average of GBX 7.15 and a 200-day simple moving average of GBX 8.27. The stock has a market cap of £32.68 million, a price-to-earnings ratio of -7.30 and a beta of 3.02.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Articles

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.